Last reviewed · How we verify
Misoprostol 50 mcg
At a glance
| Generic name | Misoprostol 50 mcg |
|---|---|
| Sponsor | Unidade Local de Saúde de Coimbra, EPE |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- postpartum hemorrhage
- clinical endometritis
- Blood transfusion
- pRBC transfusion
- wound complication
- 5 min APGAR <7
- sepsis
- Postpartum Readmission
Key clinical trials
- PROMMO Trial: Oral Misoprostol vs IV Oxytocin (EARLY_PHASE1)
- Induction of Labor in Morbidly Obese Patients (EARLY_PHASE1)
- Misoprostol Versus Dinoprostone in Induction of Labor (NA)
- Mifepristone for Labor Induction (PHASE3)
- Misoprostol Dosing in BMI Greater Than 30 (PHASE4)
- Pitocin or Oral Misoprostol for PROM IOL (PHASE4)
- Outpatient Cervical Ripening With Orally Administered Misoprostol in Diabetics (NA)
- Labor Induction With Double Balloon Device, Oral Misoprostol and Concomitant Use of Both (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Misoprostol 50 mcg CI brief — competitive landscape report
- Misoprostol 50 mcg updates RSS · CI watch RSS
- Unidade Local de Saúde de Coimbra, EPE portfolio CI